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ARTIFICIAL DEVICES AS A VIABLE ALTERNATIVE TO THE CONVENTIONAL 
HEART TRANSPLANT 
Hadassa Radzik 
ABSTRACT 
The human heart is one of the most vital organs in the body.  It distributes blood 
throughout the body, providing the body with oxygen and nutrition, and contributes to 
metabolism. When the heart fails, blood flow is impaired, thereby limiting the exchange of 
oxygen within the cardiopulmonary system as well as diminishing oxygenation and nutrition to 
the other major organs and periphery.  The only current proven treatment for advanced heart 
failure is cardiac transplant. Given the heart’s importance and the scarcity of donated organs, 
modern medicine has experimented with the creation of an artificial heart. Because the heart is 
primarily a pump controlled via electrical impulses, it lends itself to artificial replication, and 
advancements in modern engineering and medicine have turned this theory into reality. 
Currently, there are mechanical devices which can act as a bridge to transplant and, in many 
cases, improve the quality of life of their recipients. Due to a scarcity of available donor hearts as 
well as the high cost and complications associated with conventional heart transplants, it is 
imperative to do an analysis as to whether left ventricle assist devices or the total artificial heart 
are viable alternatives to conventional cardiac transplants. If the artificial devices can be as 
productive as a transplanted heart without any overt risk, they greatly expand and improve the 
prognosis of patients in end stage of heart failure.  This paper will weigh the benefits of artificial 
devices as viable alternatives for the conventional heart transplant within the different aspects of 
treatment for end stage heart failure.   
INTRODUCTION 
The body requires that all its organs and supporting systems work symbiotically to 
achieve its optimum level of health and wellness. Failure of any organ can have an effect on the 
entire system. When an organ such as the heart fails, all other bodily functions suffer. Given the 
role of the heart in oxygenation and nutrition, it is quite obvious why heart failure leads to 
decreased quality of life and eventual death. It is, thus, imperative that every effort be made to 
take care of this very necessary organ and to try to preserve its form and function for as long as 
possible.   
Heart disease is rapidly becoming one of the top killers of American men and women.  
Poor dietary habits and lack of exercise tend to lead to high cholesterol and buildup of plaque in 
the arteries, paving the way toward heart disease.  Statistics show that every 30 seconds, 
someone dies of heart failure (Debakey 2000). Such staggering numbers beg a question.  Why 
can these patients not be saved? The answer is that those who are dying have generally entered 
advanced stage IV heart failure.  Once this stage has been reached, there is little a doctor can do 
aside for transplanting a new living heart.  It is for this reason that research into the creation of a 
feasible, functional artificial heart is so crucial. 
Conventional heart transplantation is still considered the gold standard in treatment for 
end stage heart failure due to its associated successes and the overall improvement in the quality 
of life experienced by the recipients (Jovic 2011). Studies show that the survival rate for 
transplant recipients is 86% in the first year and 64% after 5 years (Jarvik 2011). Therefore, 
before analyzing the effectiveness of artificial devices as a replacement for conventional heart 
transplant, a complete understanding of the conventional transplantation procedure as well as its 
advantages and disadvantages must be gained. 
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CONVENTIONAL HEART TRANSPLANTS 
The conventional heart transplant involves surgically removing the damaged or diseased 
heart and replacing it with a healthy donor heart. Although simple in theory, this procedure is 
difficult to execute due to the scarcity of donor hearts as well as the high cost associated with it. 
In order for a heart to qualify for donation, it must meet extremely stringent requirements. The 
potential donor must be one who has been declared brain dead but still remains on life support 
and satisfies established criteria in regard to age, medical condition, cause of death, and 
psychosocial history (Massad 2004). Additionally, the donor heart must match the blood and 
tissue types of the recipient almost perfectly in order to prevent rejection. Furthermore, once the 
organ is removed from the donor, it is packed in ice in order to preserve it, leaving the surgeon 
with a maximum of four to six hours to implant it into the recipient. Thus, it is crucial that the 
recipient be ready for surgery at a moment’s notice. The convergence of all these prerequisite 
conditions is quite rare to the extent that in 2008 there were 3,500 heart transplants performed 
worldwide, while 800,000 patients were in stage IV heart failure waiting for donors (Korfer 
2007). 
The procedure of replacing a failing heart with a donor heart is complicated and invasive. 
Time, technique, and skill are of the essence. Once the donor heart is identified and allocated to a 
recipient based on certain criteria, the timetable from removal to implantation is kept to a 
minimum. At the time of procurement, the healthy donor heart is arrested by injecting into it two 
liters of potassium and covered with ice before removal. Once it is excised from the 
mediastinum, the heart is inspected for any septal defects or abnormalities. After determining 
that no defects are present, the heart is then placed in a sterile bag with slush and saline and 
transported to the transplant center. Upon the heart’s arrival at the transplant center, the recipient 
is placed on pulmonary bypass, and a cardioectomy is performed using the Lower and Shumway 
technique to remove the native heart and attach the new heart to the native left and right atrial 
cuffs (Massad 2004). 
Even if all the details of the transplant surgery are executed successfully, the transplant of 
a living heart remains fraught with many dangers and difficulties. The threat of contracting graft 
versus host disease is constant. Therefore, the patient is placed on immunosuppressive drug 
therapy to suppress the production and activity of T-cells which would attack the foreign organ 
(Jovic 2011). Consequently, routine endomyocardial biopsies must be conducted in order to 
ensure that the medication is effective and rule out acute cellular rejection. While 
immunosuppressive medication diminishes the threat of graft resistance, long-term use of 
immunosuppressive drugs is associated with renal failure as well as thromboembolic disease 
(Atasever et al. 2006). Additional complications experienced in postoperative patients include 
cardiac failure, pulmonary and systemic hypertension, and opportunistic infections such as 
pneumonia (Jovic 2011). In a study of 34 post-transplant patients, conducted by the Ege School 
of Medicine, researchers found that nearly one third of heart transplant patients die of pulmonary 
complications. In this particular study, two patients died of cardiac failure in the early 
postoperative period, and another 10 patients developed severe pulmonary complications, most 
commonly in the form of pneumonia (Atasever et al. 2006). 
ETHICAL ISSUES DUE TO SCARCITY OF DONOR HEARTS 
Due to the stringency of the criteria that a donor heart must meet in order to be suitable 
for transplant, donor hearts remain a rare commodity.  Due to issues of supply and demand, 
ethical questions arise as to whether age, physical illness, mental capacity, or value to society 
should be considered in evaluating a potential transplant recipient (Jarvik 2011). If any of these 
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factors are taken into account, there is an inherent selection bias that is present. Furthermore, it 
leads into other ethical quagmires, such as determining whose life is more valuable. Therefore, 
there are strict guidelines set by the National Health and Medical Research Council regarding the 
criteria and procedures that must be adhered to in this grey area. The Australian National Health 
and Medical Research Council put forth a set of guidelines by stating that “there should be no 
discrimination between potential recipients on the basis of… race, nationality, religious belief, 
gender, marital status, sexual orientation, social status, disability or age, except where conditions 
associated with the persons age directly determine the likelihood of a poorer outcome” 
(Macdonald 2008). Yet, many believe that these factors should be taken into consideration when 
screening potential recipients. They are, therefore, fighting to further narrow the spectrum of 
eligible recipients.  
Although conventional heart transplants are the preferred cure for advanced heart failure, 
there are many disadvantages associated with it, mainly high cost, scarcity of donor organ, and 
postoperative complications. Therefore, research into an alternative artificial device is crucial.   
ARTIFICIAL HEART IMPLANTATION
Mechanical circulatory devices have the potential to eliminate the problems that plague 
conventional heart transplants and are changing the face of heart failure therapy (Frazier et al. 
2009). Because they can be mass-produced in a factory, the scarcity of donor hearts becomes a 
non-issue, and their cost is lower. To date, approximately 15,000 artificial devices have been 
implanted worldwide, and the numbers are projected to increase (Copeland 2011). 
DEVELOPMENT OF ARTIFICIAL DEVICES
As early as 1960, researchers embarked on the road to find a permanent solution to the 
heart problem. They simultaneously pursued a technique for heart transplantation as well as a 
proposal for an implantable mechanical circulatory device that would replace the failing organ. 
Research into artificial devices focused on two types of pulsatile devices, one to replace and the 
other to aid the failing heart. One device was the total artificial heart (TAH), which would 
completely replace the failing heart, and the second device researched was the ventricular assist 
device (VAD), which would assist the failing heart in blood circulation. Both devices would be 
pulsatile and attached to an internal and external battery source to propel the motor. Additionally, 
they would have sensors to monitor and adjust the pressure at which the device pumps blood in 
order to allow for a natural beat (Morlacchi and Nelson 2011) (See Figure 1). 
Figure 1: Cardiowest TAH. 
Source: Platis and Larson 2009 
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PULSATILE TOTAL ARTIFICIAL HEART 
The total artificial heart was designed to replace and mimic the natural heart, with one 
component pumping deoxygenated blood from the heart to the lungs via the pulmonary artery 
and a second component pumping the oxygenated blood from the lungs to the heart via the 
pulmonary vein. The mechanical valves provide unidirectional flow and work complementary to 
the diaphragm during the cardiac cycle to eject the blood of the right and left ventricles. An 
attached external drive console provides controllers that give the device the ability to adjust the 
heart rate, systolic pressure, and vacuum for the ventricle. Devices like these, such as the 
Cardiowest temporary Total Artificial Heart, could produce a cardiac blood output of more than 
nine liters per minute and allow normal metabolic functions to continue. However, the earliest 
versions of these devices did not function efficiently, causing many complications, such as clot 
formation, bleeding, hypertension, and death due to failure of mechanical parts (Platis and 
Larson 2009).  Two major technical problems associated with these devices were the lack of 
appropriate materials that would not be rejected by the body and the large size of the device, 
making it poorly suited for long-term use. The device, with two components surgically implanted 
into the chest and another two into the stomach, was extremely large and heavy, requiring a lot 
of space to be implanted into the body (Morlacchi and Nelson 2011).  Additionally, other 
components, such as the large external power console located exterior to the body, confined 
patients to the hospital and inhibited improvement in their quality of life. Therefore, this model 
was phased out of use.  
LEFT VENTRICULAR ASSIST DEVICES 
  Due to the failures associated with the total artificial heart, researchers turned their focus 
to the smaller ventricular assist device in the 1980s. The device is most commonly referred to as 
left ventricular assist device (LVAD) because the majority of the pumping work of the heart is 
done by the left ventricle. The objective of this device was to act as an alternative to organ 
transplant and aid the heart in its pumping of the blood and regulation of the heartbeat.  This was 
accomplished through implantation of the device near or within the heart, with a direct 
connection to the heart, causing a complete bypass of blood flow to the left ventricle. This 
technique allowed the blood to flow through the pump, eliminating the symptoms caused by 
ventricular failure, thereby providing complete support of the circulation of blood within the 
patient’s body (Morlacchi and Nelson 2011). 
Because the left ventricular assist device is less technically demanding, researches and 
developers have been able to achieve quick advancement in a relatively short amount of time. 
There have been major improvements in its size, durability, simplicity, and ease of implantation 
within the last 20 years. A very significant improvement in the device has been the 
implementation of self-contained mechanisms that have eliminated the need for an external 
driver (Morshuis et al. 2010). The small size of the device allows for the pumps as well as the 
additional components to be implanted into the body. Additionally, due to its small size, the 
implantation procedure does not require a complete opening of the chest, reducing the amount of 
recovery time following surgery (Morlacchi and Nelson 2011). Moreover, the introduction of 
batteries as a rechargeable external power source allowed patients to have a small external 
battery and controller attached to them, thereby promoting mobility and allowing patients to 
return home, improving their quality of life.   
The design of the left ventricular assist device has evolved from the first-generation 
pulsatile volume displacement pump to the more commonly used second-generation continuous 
flow pump. The pulsatile volume displacement pump was designed to simulate the natural 
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heartbeat during the circulation of blood from systemic circulation to pulmonary circulation and 
vise versa. It mimicked the natural pulsing action of the heart with its own pulsatile action, 
sucking the blood from the left ventricle into the pump and then forcing it out into the aorta. It 
consisted of inflow and outflow valves as well as a diaphragm to exert pressure on the blood, 
causing a natural pulse. The typical stroke volume associated with these pumps was 50-70ml, 
with the afterload of the device depending on the amount of blood that filled the device during 
the preload period (Copeland 2011). 
The more recent continuous flow device (see Figure 2) uses either an axial flow pump or 
a centrifugal pump to provide pulseless circulation of blood throughout the body.  Both pumps 
use rapidly spinning rotors to enable continuous blood flow. The axial pump design includes a 
magnetically suspended motor which rotates the axial pump without any physical contact. In this 
design, the rotor is the sole moving part, and the additional components of the motor, the two 
stators, are “passively stable” and are “controlled according to the rotors position so as to levitate 
the rotor” (Okada et al. 2003). These motors can spin up to 8000-10000 rpm, thereby facilitating 
the blood in reaching all the necessary destinations in systemic circulation (Copeland 2011). 
The centrifugal pump design is very similar to the axial pump with exception to its size. 
It is somewhat larger than its axial pump counterpart, but is more energy efficient. It has a 
circular shape and uses a rotating impeller, which can have numerous blades, to create flow. The 
average speed of the motor is 2000 rpm, generating an output of eight liters per minute, and the 
hydraulic flow is from the left side while the inflow is from the right. A negative side effect 
associated with both of these models is the formation of clots around the bearings of the motor 
that are lubricated by the blood (Anderson et al. 2000). 
Figure 2: Components of the Continuous-Flow 
LVAD. Source: Pagani et al. 2009 
(A) The inflow cannula is inserted into the apex 
of the left ventricle, and the outflow cannula is 
anastomosed to the ascending aorta. Blood exits 
through the left ventricular apex and into the left 
ventricular assist device (LVAD), which pumps 
throughout cardiac diastole and systole into the 
ascending aorta.  
(B) The LVAD pump is placed within the 
abdominal wall or peritoneal cavity. A 
percutaneous lead carries the electrical cable to 
an electronic controller and battery packs, which 
are worn on a belt and shoulder holster, 
respectively. 
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Researchers used the success of the continuous flow left ventricular assist device as a 
blueprint for a model of a new artificial heart that would completely replace the native heart with 
the implantation of two continuous flow devices working in tandem. This device is an 
improvement of the original total artificial heart in size, reliability, function, and energy 
efficiency. The continuous flow total artificial heart (CFTAH) consists of two rotary pumps 
which control the systemic and pulmonary circulation. Instead of mimicking the natural 
heartbeat by pumping the blood, they allow for the continuous flow of blood through the body 
using the mechanisms discussed above. Since little is known about the physiological effects of 
pulseless circulation of blood, it is currently undergoing phase II animal trials (Frazier et al. 
2009). 
DISADVANTAGES AND ADVERSE SIDE EFFECTS 
The disadvantages and complications associated with the artificial models are numerous 
and include the biomaterial used to make the device, mechanical failures, and blood clotting. The 
procurement of a suitable biomaterial with which to make the artificial device has proven 
difficult, because antibodies in the blood tend to react with almost all manmade substances, 
causing infection.  Therefore, developers are currently coating the internal and external surfaces 
of the device with polyurethane, which has demonstrated compatibility, to reduce the potential 
for infection. Additionally, researchers at the Milwaukee Heart Institute are attempting a method 
of lining the device with the patient’s own endothelial cells. This is done by removing cells from 
the inner lining of the stomach through a procedure similar to liposuction, culturing them in a 
lab, and subsequently growing them on the device (Cecchin and Pfeiffer 1993). 
Researchers are addressing the side effect of thrombi formation around the movable parts 
of the motors resulting in thromboembolism (stroke). The clotting is a result of the minimal 
clearance space between the device and the myocardial tissue, which interferes with the blood 
flow patterns. In order to prevent this, there is a need to improve the model of the motor by 
providing additional clearance space or with a mechanism to prevent clotting (Anderson et al 
2000). Currently, patients with implanted left ventricular assist devices are prescribed long-term 
antithrombotic therapy in order to prevent the formation of clots (Pagani et al 2009).  
Additional risk associated with implantation of mechanical devices is death due to failure 
of mechanical parts. Although the device is small in size, there are many mechanisms involved 
in the delivery of energy to the motor which powers the pump. If any of the components fail, 
there is a narrow window of time during which the patient can survive without replacing the 
component. Therefore, patients are given additional battery packs to prevent death due to failure 
of an external component. Nevertheless, if there is a glitch in any of the internal components or 
in case of a power failure, there is little that can be done for the patient at that point. Therefore, 
these mechanisms need continuous improvement in their reliability and durability to prevent 
such failures from occurring.   
EXPERIMENTATION AND STUDIES 
There are various models for artificial devices to replace or aid a failing heart. Therefore, 
experimental testing is needed to determine which designs are effective and what improvements 
must be made to ensure minimal adverse side effects.  Once the development phase of the device 
is complete, there are various stages in the rigorous experimental process. Experimentation 
begins with phase I testing (i.e. in vitro), during which the device is placed in a simulated human 
body environment with a mock circulatory system in place (Morlacchi and Nelson 2011). The 
device is then tested in regard to implantation techniques, size, mechanical operation of parts, 
motor efficiency, battery life, durability, reliability, and adaptation to various stimuli. According 
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to the successes or failures of the various aspects of the device, certain modifications are made in 
the model.   
Once phase I is complete, barring any complications, the researchers move forward to 
phase II testing, in which they implant the device in an animal with a failing heart and monitor 
the various improvements as well as complications that arise in the operative and postoperative 
stages.  If the device passes animal trial, it proceeds to clinical trials and is usually implanted in 
patients who are not eligible for cardiac transplant.  The clinical trials are primarily for testing of 
surgical implantation technique, effectiveness and durability of the devices, as well as any 
complications that may arise due to the device.  
Jack G. Copeland and colleagues conducted a clinical trial to provide comprehensive 
analysis as to the efficacy of the CardioWest temporary total artificial heart, a pulsatile total 
artificial heart. The patients in the protocol group were in acute heart failure and at high risk of 
imminent death. These patients did not meet criteria for left ventricular assist devices for 
different reasons, and their last resort was to receive the total artificial heart while waiting for a 
heart transplant. In this particular study, 79% of the protocol group survived to receive a heart 
transplant versus 49% of the control group. Furthermore, immediately after implantation, the 
protocol group’s mean arterial pressure rose and their mean venous pressure dropped 
significantly, showing the effectiveness of the device. Although the results of the analysis look 
promising, there were many ensuing adverse effects associated with the implantation of the total 
artificial heart, including loss of blood, device malfunction, the large size of the device (limiting 
the population size which can receive the implant only to those with enough space in their 
mediastinum), and death (Copeland et al. 2004). These results indicate that the total artificial 
heart is not the ideal artificial device to be used as a replacement for a failing heart.  
Clinical trials for the HeartMate continuous flow left ventricular assist device (see Figure 
3) began in 2003. The trials consisted of 18 months of follow up data on 281 patients who, in 
urgent need of heart transplant, underwent the implantation of the HeartMate left ventricular 
assist devices. The trial results showed that patients exhibited greater survival rates, less frequent 
adverse events, and improved reliability with continuous flow left ventricular assist devices as 
compared to pulsatile flow devices. At 18 months, of the 281 patients in the trial, 157 had 
meanwhile received heart transplants, 58 were living mobile lives with left ventricular assist 
devices in their bodies, seven had their left ventricular assist devices removed due to recovery of 
their hearts, 56 had died, and three had been removed from the trial after exchanging their 
devices for another type of device. The results demonstrated that heart function had significantly 
improved after six months of LVAD support as compared to the pre-LVAD baseline. Although 
the results seem promising, there were many side effects associated with this device, including 
sepsis, stroke, multi-organ failure, bleeding, and device malfunction. Therefore, additional 
improvement is called for in order for this model to be considered for the vast majority of end 
stage heart failure patients (Pagani et al. 2009). 
 
 
 
 
Figure3: HeartMate II Left 
Ventricular Assist System. Source: 
FDA 2009 
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Phase II trials conducted by the Texas Heart Institute tested the physiological effects of 
the continuous flow total artificial heart implanted in a calf.  The findings were significant. On 
postoperative day one, the calf was standing for several hours at a time, and by day three the calf 
was eating a full diet and had been weaned off the ventilator. Throughout the study, the calf 
gained six pounds and was able to recognize its keepers and sleep at regular intervals. The 
pumps operated without mechanical problem over the course of the study. The most promising 
success the calf had was running on the treadmill for 40 minutes with no sign of exhaustion. The 
left and right pumps increased in response to increased oxygen need without any external 
adjustments, and the calf’s breathing remained normal. The calf demonstrated overall improved 
quality of life and overall improvement of metabolic functions. While this study had promising 
results, the calf was euthanized on day 48 due to a glitch in the left axial pump. Although the 
results of the study were promising to the extent of the device’s success, the fact remains that the 
calf only survived 48 days, demonstrating that the device is a long way from being considered a 
viable replacement for the heart (Frazier et al. 2009). 
CONCLUSION 
  Based on numerous studies that have been conducted, it is evident that the development 
of an artificial device that will completely replace the failing heart is still in its early stages. The 
various problems associated with the device prevent it from being considered a viable long-term 
solution for replacement of a failing heart.  Although there is no current long-term solution for 
the problems associated with conventional heart transplants, the future for patients in end stage 
heart failure looks bright. Over the next few decades, researchers hope to perfect the model of 
the total artificial heart to the extent that it will be a long-term solution for those in need of a new 
heart. Additionally, successes associated with left ventricular assist device implantation as a 
temporary bridge, aiding the failing heart until a real heart is available for transplant, are 
allowing for more devices to receive FDA approval, subsequently leading to an increased 
number of implantations. Therefore, these devices should be considered while weighing the 
options for a patient diagnosed with advanced stage heart failure.  
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